MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6749
-0.0009
-0.13%
Opening 15:02 07/14 EDT
OPEN
0.6800
PREV CLOSE
0.6758
HIGH
0.6989
LOW
0.6720
VOLUME
281.30K
TURNOVER
--
52 WEEK HIGH
1.540
52 WEEK LOW
0.3700
MARKET CAP
74.52M
P/E (TTM)
-0.8312
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SESN stock price target is 3.417 with a high estimate of 5.00 and a low estimate of 2.250.

EPS

SESN News

More
Sesen Bio Inc - On July 3, Received A Product-specific Pediatric Waiver From The European Medicines Agency For Vicineum
On July 3, 2020, Sesen Bio, Inc. (the “Company”) received a product-specific pediatric waiver from the European Medicines Agency (“EMA”) for Vicineum™ (oportuzumab monatox), the
Benzinga · 07/06 11:35
Sesen Bio In 8K Announces FDA Conditionally Accepts Brand Name VICINEUM For Company's Product Candidate
Benzinga · 06/18 12:26
Edited Transcript of SESN earnings conference call or presentation 11-May-20 12:00pm GMT
Q1 2020 Sesen Bio Inc Earnings Call
Thomson Reuters StreetEvents · 06/12 08:04
Should You Avoid Sesen Bio, Inc. (SESN)?
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. I
Insider Monkey · 06/05 19:18
Sesen Bio (SESN) Presents At Jefferies Virtual Healthcare Conference - Slideshow
Seeking Alpha - Article · 06/03 20:07
Sesen Bio to Present at the Jefferies Virtual Healthcare Conference
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tue
Business Wire · 05/26 11:00
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Kirkland's, Inc. (NASDAQ: KIRK) shares rose 54.3% to $1.30 in pre-market trading after the company said e-commerce demand was up 96% in the period since stores closed on March 19th.
Benzinga · 05/19 11:20
Sesen Bio, Inc. (SESN) CEO Dr. Thomas Cannell on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/11 17:32

Industry

Biotechnology & Medical Research
+1.48%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Symbol
Price
%Change

About SESN

Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.
More

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.